Astel­las flesh­es out more PhI­II da­ta for Claudin 18.2 drug

Just weeks af­ter un­veil­ing the first de­tailed late-stage da­ta on its CLDN18.2 drug, Astel­las is beef­ing up the da­ta pack­age with re­sults from a sec­ond Phase III tri­al.

We al­ready knew that adding Astel­las’ zol­be­tux­imab to a chemother­a­py reg­i­men called CAPOX spurred a sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ment in pro­gres­sion-free sur­vival for stom­ach can­cer pa­tients, but the com­pa­ny is now spec­i­fy­ing by how much. The com­bi­na­tion of zol­be­tux­imab plus CAPOX (a reg­i­men that in­cludes capecitabine and ox­ali­platin) re­duced the risk of pro­gres­sion or death by 31.3% (p=0.0007), meet­ing the pri­ma­ry end­point.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER